Document Type : Original Article

Authors

1 Department of Hematology and Blood Bank, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

2 Cancer Molecular Pathology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

3 Social Determination of Health Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

10.30476/mejc.2021.90564.1580

Abstract

Background: The B-cell-specific Moloney murine leukemia virus integration site1 (BMI-1) is one of the famous members of the Polycomb ring finger group, which plays a crucial role in the gene transcription regulation through histone changes. Hence, it is believed to be necessary to further clarify the effects of the BMI-1 clinical.
Method: This cross-sectional study was conducted on 70 acute myeloid leukemia (AML), 70 chronic myeloid leukemia (CML), and 20 healthy individuals, as the control group. We used Real-Time quantitative polymerase chain reaction (Real-Time PCR) in order to assess the BMI-1 level expression and its effect on prognosis in AML patients in the Molecular Pathology Research Center.
Results: The results of the present work indicated that the BMI-1 overexpression was significantly higher in the AML and CML patients compared to that in the healthy controls (P < 0.001). Furthermore, a significant relationship was observed between the BMI-1 overexpression and poor prognosis in the AML patients (Hazard ratio=1.749, P < 0.001, 95% confidence interval = 1.31-2.32). Additionally, BMI-1high was found in chronic and blastic phase in the CML patients (P < 0.001).
Conclusion: We concluded that investigation of BMI-1 gene expression pattern will be conducive to the prognosis and treatment of myeloid leukemia.

Keywords

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination, and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi:10.30476/mejc.2021.90564.1580